title: Site of effect of LY2951742 for migraine prophylaxis--authors' reply.
authors.affiliation: Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: dodick.david@mayo.edu.
authors.forename: David W
authors.initials: DW
authors.lastname: Dodick
authors.affiliation: NIHR Wellcome Trust Clinical Research Facility, King's College London, London, UK.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Goadsby
authors.affiliation: Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Egilius L H
authors.initials: EL
authors.lastname: Spierings
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Joel C
authors.initials: JC
authors.lastname: Scherer
authors.affiliation: Arteaus Therapeutics, Cambridge, MA, USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Sweeney
authors.affiliation: Arteaus Therapeutics, Cambridge, MA, USA.
authors.forename: David S
authors.initials: DS
authors.lastname: Grayzel
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015740:Calcitonin Gene-Related Peptide